Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex

AIDS Care. 2024 Jan;36(1):80-86. doi: 10.1080/09540121.2023.2198187. Epub 2023 Apr 17.

Abstract

We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase III trial in Malawi, South Africa, Uganda, and Zimbabwe, 2012-2015; n = 2629). Transactional sex was defined as receipt of money, goods, gifts, drugs, or shelter in exchange for sex in the past year. Dimensions of acceptability included: ease of use and physical sensation in situ, impacts on sex, partner's opinion, and likelihood of future use. We used Poisson regression models with robust standard errors to compare risk of acceptability challenges by baseline history of transactional sex. At product discontinuation, women exchanging sex found the ring comfortable (90%), easy to insert (92%) and nearly all (96%) were likely to use the ring in the future. Women who had exchanged sex were more likely to report feeling the ring during sex (ARR 1.43, 95% CI: 1.09, 1.89; p = 0.01) and slightly more likely to mind wearing the ring during menses (ARR 1.22, 95% CI: 1.01, 1,46; p = 0.04) and during sex (ARR 1.22, 95% CI: 1.02, 1.45; p = 0.03). Messaging and counseling should include enhanced support for use during sex and menses to support optimal use.

Keywords: HIV prevention; acceptability; sub-saharan Africa; transactional sex; vaginal ring; women.

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Contraceptive Devices, Female*
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • HIV-1*
  • Humans
  • Pyrimidines*

Substances

  • Anti-HIV Agents
  • Dapivirine
  • Pyrimidines